kojoX™
Revolutionizing bioproduction to accelerate and de-risk global supply chains
“Kojo” is the Japanese word with two meanings – ‘improvement’ and ‘factory’. We have internalized that philosophy and called it ‘kojoX™’ to signify the exponential impact we aim to make in transforming the bioproduction industry. kojoX is our innovative approach to the design and build of a modular, agile bioproduction network that enables scale, speed and resilient supply chain assurance so our biopharma customers can deliver life changing medicines to patients faster.
We understand the critical challenges of manufacturing supply and capacity constraints, regulatory complexity, and geopolitical risks that lead to inefficiencies in the supply chain, inhibiting rapid clinical development and patient access to new medicines.
Our policy of building a resilient supply chain to mitigate geopolitical risks translates into procuring 95% of our raw materials from the US, Europe and Japan, which keeps us as close as possible to our customers’ markets and their patients.
Our innovative kojoX bioproduction ecosystem is being built for agility, scalability and efficiency across our strategic locations in the US, UK, Denmark and Japan, allowing biopharma companies access to modular, scalable manufacturing capacity that meets demands from early clinical development to commercial launch.
Our global network is built with a harmonized design of our production facilities equipment, processes, and quality systems. This harmonized design enables validated drug substance API processes to transfer to new, equivalent production lines within our network – delivering scalability and faster technology transfers for our customers and a more sustainable production process for our environment.
kojoX is transforming the CDMO space by offering unprecedented agility, flexibility, and replicability. With our fully integrated global network we ensure our partners have access to a network of possibilities, from early development to scalable commercialization. kojoX enables us to meet capacity demands seamlessly, shortening tech transfers and regulatory processes, enabling our partners to bring medicines to patients faster and more efficiently while providing supply chain agility and security of supply.
Lars Petersen I President & CEO
kojoX in action:
Our modular approach for designing and building our expansions in Hillerød, Denmark and Holly Springs, NC, USA, and Toyama, Japan allows us to build exponentially faster as the degrees of replication increase, providing our customers with:
kojoX roadmap:
Our capital investment roadmap through 2028 will support expansion of our existing biomanufacturing capabilities and capacity in Holly Springs, NC; College Station, TX; Billingham, UK; Hillerød, DE; , and Toyama, Japan. With our kojoX blueprint, every investment in expansion to our network will increase our global bioproduction capacity, provide faster technology transfer and the scalability needed to meet market demand – regardless of the manufacturing location.
kojoX is another example of how we put our ‘Partners for Life’ vision into action. By putting our people first, transforming the industry through innovation and expertise, and providing unprecedented delivery, we remain dedicated to fulfilling our promises and ensuring that our global network supports the production of life-changing medicines that improve patients’ lives.
